AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Apyx Medical Corporation
Video analysis: APYX
All videosNo video analysis for this stock yet. Request one from our team.
News: APYX
Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.
Apyx Medical Corporation (NASDAQ:APYX) Receives $6.60 Consensus Target Price from Brokerages
Apyx Medical Corporation (NASDAQ: APYX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has given
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical Q2 Earnings Call Highlights
Apyx Medical NASDAQ: APYX reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces.
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6th.
